The blockade of TNFα expression in T17M mice with a rhodopsin (RHO) mutation (a model of RP) or the use of antibodies against TNFα (e.g., adalimumab) in rd10 mice slow down photoreceptor death [28,38,41], suggesting that it may be an attractive therapeutic target. This evidence concerns the gene RHO and retinitis pigmentosa 1.